My current clinic trials are examining how biologic therapies may control psoriasis. These trials are attempting to identify psoriasis patients not responding to TNF-antagonists and changing the biologic strategy to control psoriasis . Other trials are using new biologic agents, such as a monoclonal antibody to IL-22 to assess the efficacy and safety in treating psoriasis.
Our keloid clinic is a specialty clinic intended to study etiologies and treatmnet options for these disfiguring fibrotic tumors. At this time we do not have any trials active for keloids.